Abstract
BackgroundFor some patients with Immune Mediated Rheumatic Disease (IMRD) discontinuing 1st line treatment with a subcutaneous Tumor Necrosis Factor-alpha inhibitor (SC-TNFi), 2nd line treatment with another SC-TNFi may be appropriate.ObjectivesThe...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have